10-Q · May 4, 2026
Organon reported declining financial performance for Q1 2026, with revenue of $1.460 billion and diluted EPS of $0.71, both missing analyst expectations. Notably, segments saw declines in Women’s Health and Established…
Earnings analysis · 10-Q
OGN earnings analysis
Filed October 30, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include current-quarter income statement, balance-sheet, cash-flow, or segment results, so revenue, margins, EPS, free cash flow, and year-over-year trends cannot be assessed from the…
Read full summary
The extracted 10-Q text does not include current-quarter income statement, balance-sheet, cash-flow, or segment results, so revenue, margins, EPS, free cash flow, and year-over-year trends cannot be assessed from the filing excerpt. Management reported effective disclosure controls as of September 30, 2026, no material internal-control changes during the quarter, and no changes in market-risk exposure. No quantitative guidance was provided, and the company reported no material changes to previously disclosed risk factors.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective as of September 30, 2026, providing reasonable assurance that required information is reported timely.
-
Internal controls unchanged
The company reported no changes in internal control over financial reporting during the quarter ended September 30, 2026, that materially affected or were reasonably likely to materially affect those controls.
-
Market-risk exposure unchanged
Organon reported no changes to its market-risk exposure during the quarter ended September 30, 2026, relative to the disclosures in its December 31, 2025 Form 10-K.
-
No insider trading-plan changes
No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended September 30, 2026.
What to watch
-
No updated risk-factor detail
The filing states there were no material changes in risk factors from those disclosed in the December 31, 2025 Form 10-K and the March 31, 2026 Form 10-Q; therefore, this excerpt provides no updated quantification of existing risks.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text; outlook may be addressed separately in the earnings release or call.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.